Galapagos NV (GLPGF)
USD 22.39
(0.0%)
USD 22.39
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 327.98 Million EUR | -50.67% |
| 2022 | 760.72 Million EUR | 17.25% |
| 2021 | 648.81 Million EUR | -1.2% |
| 2020 | 656.68 Million EUR | 38.34% |
| 2019 | 474.69 Million EUR | 42.27% |
| 2018 | 333.64 Million EUR | 53.83% |
| 2017 | 216.89 Million EUR | 53.81% |
| 2016 | 141.01 Million EUR | 9.3% |
| 2015 | 129 Million EUR | 22.49% |
| 2014 | 105.32 Million EUR | -0.99% |
| 2013 | 106.37 Million EUR | 17.95% |
| 2012 | 90.18 Million EUR | 2251.07% |
| 2011 | 3.83 Million EUR | -22.05% |
| 2010 | 4.92 Million EUR | -18.77% |
| 2009 | 6.05 Million EUR | -90.12% |
| 2008 | 61.3 Million EUR | 20.23% |
| 2007 | 50.98 Million EUR | 90.21% |
| 2006 | 26.8 Million EUR | 109.74% |
| 2005 | 12.78 Million EUR | 26.57% |
| 2004 | 10.09 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 106.74 Million EUR | -74.72% |
| 2024 Q1 | 102.4 Million EUR | 181.09% |
| 2023 Q3 | 144.56 Million EUR | -7.55% |
| 2023 FY | 375.3 Million EUR | -50.67% |
| 2023 Q1 | 153.32 Million EUR | -31.38% |
| 2023 Q2 | 156.37 Million EUR | 1.99% |
| 2023 Q4 | -126.27 Million EUR | -187.35% |
| 2022 Q2 | 211.31 Million EUR | 36.7% |
| 2022 Q1 | 154.58 Million EUR | -0.83% |
| 2022 FY | 760.72 Million EUR | 17.25% |
| 2022 Q4 | 223.44 Million EUR | 30.37% |
| 2022 Q3 | 171.39 Million EUR | -18.89% |
| 2021 FY | 648.81 Million EUR | -1.2% |
| 2021 Q2 | 186.52 Million EUR | 13.26% |
| 2021 Q4 | 155.87 Million EUR | 9.87% |
| 2021 Q3 | 141.86 Million EUR | -23.94% |
| 2021 Q1 | 164.69 Million EUR | 2.97% |
| 2020 Q2 | 189.81 Million EUR | 32.96% |
| 2020 Q4 | 159.94 Million EUR | -2.58% |
| 2020 FY | 656.68 Million EUR | 38.34% |
| 2020 Q1 | 142.75 Million EUR | 0.54% |
| 2020 Q3 | 164.17 Million EUR | -13.51% |
| 2019 Q2 | 103.1 Million EUR | 19.49% |
| 2019 Q1 | 86.29 Million EUR | -11.65% |
| 2019 FY | 474.69 Million EUR | 42.27% |
| 2019 Q4 | 141.99 Million EUR | -0.91% |
| 2019 Q3 | 143.3 Million EUR | 38.99% |
| 2018 Q2 | 83.42 Million EUR | 19.28% |
| 2018 Q4 | 97.67 Million EUR | 18.24% |
| 2018 FY | 333.64 Million EUR | 53.83% |
| 2018 Q3 | 82.6 Million EUR | -0.99% |
| 2018 Q1 | 69.94 Million EUR | 5.23% |
| 2017 Q2 | 48.6 Million EUR | 7.5% |
| 2017 Q1 | 45.21 Million EUR | 6.35% |
| 2017 FY | 216.89 Million EUR | 53.81% |
| 2017 Q3 | 56.59 Million EUR | 16.43% |
| 2017 Q4 | 66.46 Million EUR | 17.44% |
| 2016 Q2 | 35.62 Million EUR | 29.48% |
| 2016 Q1 | 27.51 Million EUR | -17.57% |
| 2016 Q3 | 35.34 Million EUR | -0.8% |
| 2016 FY | 141.01 Million EUR | 9.3% |
| 2016 Q4 | 42.52 Million EUR | 20.3% |
| 2015 FY | 129 Million EUR | 22.49% |
| 2015 Q4 | 33.38 Million EUR | 0.01% |
| 2015 Q3 | 33.37 Million EUR | 3.91% |
| 2015 Q2 | 32.12 Million EUR | 6.61% |
| 2015 Q1 | 30.12 Million EUR | -2.38% |
| 2014 FY | 105.32 Million EUR | -0.99% |
| 2014 Q4 | 30.86 Million EUR | 27.69% |
| 2014 Q3 | 24.17 Million EUR | 504.93% |
| 2014 Q1 | 3.99 Million EUR | -59.23% |
| 2014 Q2 | 3.99 Million EUR | 0.0% |
| 2013 FY | 106.37 Million EUR | 17.95% |
| 2013 Q1 | 10.67 Million EUR | 0.0% |
| 2013 Q2 | 10.67 Million EUR | 0.0% |
| 2013 Q4 | 9.8 Million EUR | 0.0% |
| 2013 Q3 | 9.8 Million EUR | -8.18% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | 90.18 Million EUR | 2251.07% |
| 2011 FY | 3.83 Million EUR | -22.05% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 FY | 4.92 Million EUR | -18.77% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 FY | 6.05 Million EUR | -90.12% |
| 2008 FY | 61.3 Million EUR | 20.23% |
| 2007 FY | 50.98 Million EUR | 90.21% |
| 2006 FY | 26.8 Million EUR | 109.74% |
| 2005 FY | 12.78 Million EUR | 26.57% |
| 2004 FY | 10.09 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | -8884.205% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -24348.453% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -12382.75% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -1009.826% |
| GB Sciences, Inc. | 1.42 Million USD | -22989.4% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -9532.57% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -148932.161% |
| Skye Bioscience, Inc. | 13.54 Million USD | -2321.006% |
| Zenith Capital Corp. | 8.94 Million USD | -3567.528% |
| Agentix Corp. | 1.37 Million USD | -23810.01% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -6405.04% |
| Biomind Labs Inc. | 994.18 Thousand USD | -32890.64% |
| ContraFect Corporation | 56.88 Million USD | -476.539% |
| CSL Limited | 3.44 Billion USD | 90.49% |
| CytoDyn Inc. | 18.05 Million USD | -1716.297% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -17492.377% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -84092.922% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -471.008% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -78841.896% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -21738.153% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -35415.262% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -780.368% |
| SQZ Biotechnologies Company | 85.61 Million USD | -283.077% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -15909.479% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -277.931% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -11146.933% |
| Mesoblast Limited | 5.9 Million USD | -5457.218% |
| Marizyme, Inc. | 19.23 Million USD | -1604.729% |
| Genus plc | 147.7 Million USD | -122.063% |
| Pharming Group N.V. | 225.49 Million USD | -45.455% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -3833.169% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -22079.987% |
| IMV Inc. | 37.7 Million USD | -769.779% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -11654.302% |
| MultiCell Technologies, Inc. | 567.42 USD | -57803114.55% |
| ONE Bio Corp. | 6.44 Million USD | -4989.89% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -281.624% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -1227.077% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -18539.035% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -4782.201% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1312048.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -1948.608% |
| Alpha Cognition Inc. | 9.7 Million USD | -3279.358% |
| Enzolytics Inc. | 2.17 Million USD | -14948.678% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 78.612% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -31316.379% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -13538.087% |
| Genscript Biotech Corporation | 825.34 Million USD | 60.261% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -6569.231% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -125216.935% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -13258.234% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -191136.028% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -16974.599% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -3635.941% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -7339.587% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -8654.68% |
| Helix BioMedix, Inc. | 1.97 Million USD | -16531.914% |
| EV Biologics, Inc. | 531.96 Thousand USD | -61556.096% |
| Q BioMed Inc. | 3.43 Million USD | -9443.861% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -2918.193% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -230.199% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | -1327.594% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -17773.026% |
| HST Global, Inc. | 140.9 Thousand USD | -232668.422% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -24460.385% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -29056.733% |
| Halberd Corporation | 74.84 Thousand USD | -438139.224% |
| Resverlogix Corp. | 12.71 Million USD | -2480.137% |
| Cell Source, Inc. | 4.32 Million USD | -7482.908% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -20667.149% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -4386.664% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -1882610.522% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -13196.262% |
| Kadimastem Ltd | 2.41 Million USD | -13508.787% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -7638.437% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -180624.027% |
| LadRx Corporation | 3.81 Million USD | -8504.538% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -35415.262% |
| Affymax, Inc. | 39.38 Million USD | -732.75% |
| Itoco Inc. | 919.14 Thousand USD | -35584.001% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -29210.724% |
| Mobile Lads Corp. | 554.54 Thousand USD | -59045.139% |
| International Stem Cell Corporation | 5.27 Million USD | -6122.482% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | -8485.717% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -1303038.782% |
| Qrons Inc. | 643.67 Thousand USD | -50855.215% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -23001.06% |
| SYBLEU INC | 160.87 Thousand USD | -203775.656% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -14608.735% |
| Rebus Holdings, Inc. | 664 Thousand USD | -49295.633% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -17957.776% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -622951.936% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -1612184.324% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -804.393% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -20171.137% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -44473.444% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -10442.816% |
| Neutra Corp. | 243.82 Thousand USD | -134419.586% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1778.828% |
| PureTech Health plc | 144.59 Million USD | -126.828% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -1500.726% |
| IXICO plc | 4.7 Million USD | -6868.069% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -3628.396% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -178.55% |
| CSL Limited | 3.89 Billion USD | 91.575% |
| Cellectis S.A. | 97.32 Million USD | -237.019% |